

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported)
January 12, 2021**

IGM Biosciences, Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-39045
(Commission
File Number)

77-0349194
(IRS Employer
Identification No.)

**325 E. Middlefield Road
Mountain View, CA 94043**
(Address of principal executive offices, including zip code)

(650) 965-7873
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|--|----------------------|--|
| Common Stock, par value \$0.01 per share | IGMS | The Nasdaq Global Select Market |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On January 12, 2021, IGM Biosciences, Inc. (the "Company") released its unaudited cash and investments balance for the year ended December 31, 2020 by posting an updated corporate deck on the "Investors" page of the Company's website (www.igmbio.com). The text of such released financial information is attached hereto as Exhibit 99.1.

All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

| Exhibit No. | Description |
|------------------------|--|
| 99.1 | IGM Biosciences, Inc. Financial Information. |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IGM BIOSCIENCES, INC.

By: /s/ Misbah Tahir

Misbah Tahir
Chief Financial Officer

Date: January 12, 2021

IGM Overview

Global leaders in the development of engineered IgM antibodies for therapeutic use

Lead Programs

| | | |
|---------------|-----------------------------|--|
| CD20 x CD3 | Non-Hodgkin's Lymphoma | Phase 1 in R/R B cell NHL underway |
| DR5 | Solid and Heme Malignancies | Phase 1 in solid tumors & NHL underway |
| IL-15 x PD-L1 | Solid and Heme Malignancies | IND filing: 2021 (anticipated) |

Proprietary IgM antibody technology: 28 patent families

Strategy: extend our global leadership in the development of engineered IgM antibodies

- Advance product candidates and increase research and development efforts
- Build and control manufacturing capabilities
- Participate in commercialization if approved
- Expand intellectual property portfolio

\$366 Million Cash and Investments Balance, December 31, 2020 (Unaudited)

